1. Home
  2. Labeler Index
  3. Genentech, Inc.
  4. 50242-617
  5. NDC Package Code: 50242-617-01 Xofluza

NDC Package 50242-617-01 Xofluza

Baloxavir Marboxil Granule, For Suspension Oral - View Billable Units, 11-Digit Format, RxNorm

Table of Contents

    1. Package Information
    2. Frequently Asked Questions

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
50242-617-01
Package Description:
1 PACKET in 1 CARTON / 1 GRANULE, FOR SUSPENSION in 1 PACKET
Product Code:
50242-617
Proprietary Name:
Xofluza
Non-Proprietary Name:
Baloxavir Marboxil
Substance Name:
Baloxavir Marboxil
Usage Information:
Baloxavir marboxil is an antiviral medication used to treat the flu (influenza) if your symptoms started less than 48 hours ago. It helps make the symptoms (such as stuffy nose, cough, sore throat, fever/chills, aches, tiredness) less severe and may shorten the recovery time by 1 to 2 days. Baloxavir marboxil works by stopping the flu virus from growing. It will not treat other kinds of infection besides the flu virus. Baloxavir marboxil is not a substitute for the flu vaccine. (See also Notes section.)
11-Digit NDC Billing Format:
50242061701
NDC to RxNorm Crosswalk:
Product Type:
Human Prescription Drug
Labeler Name:
Genentech, Inc.
Dosage Form:
Granule, For Suspension - A small medicinal particle or grain made available in its more stable dry form, to be reconstituted with solvent just before dispensing to form a suspension; the granules are so prepared to contain not only the medicinal agent, but the colorants, flavorants, and any other desired pharmaceutic ingredient.
Administration Route(s):
Oral - Administration to or by way of the mouth.
Active Ingredient(s):
BALOXAVIR MARBOXIL 40 mg/1
Pharmacologic Class(es):
Sample Package:
No
FDA Application Number:
NDA214410
Marketing Category:
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date:
05-30-2025
Listing Expiration Date:
12-31-2026
Exclude Flag:
N
Code Structure:

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the disclaimer below.

Frequently Asked Questions

What is NDC 50242-617-01?

The NDC Packaged Code 50242-617-01 is assigned to a package of 1 packet in 1 carton / 1 granule, for suspension in 1 packet of Xofluza, a human prescription drug labeled by Genentech, Inc.. The product's dosage form is granule, for suspension and is administered via oral form.

Is NDC 50242-617 included in the NDC Directory?

Yes, Xofluza with product code 50242-617 is active and included in the NDC Directory. The product was first marketed by Genentech, Inc. on May 30, 2025 and its listing in the NDC Directory is set to expire on December 31, 2026 if the product is not updated or renewed by the manufacturer.

What is the 11-digit format for NDC 50242-617-01?

The 11-digit format is 50242061701. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

This package code is originally configured in a 5-3-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
5-3-250242-617-015-4-250242-0617-01